Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis

Overview

Journal Neurol Ther

Publisher Springer

Specialty Neurology

Date 2017 Jul 15

PMID 28707076

Citations 2

Authors

Richard K Bogan

Jed Black

Todd Swick

Mortimer Mamelak

Ruzica Kovacevic-Ristanovic

Kathleen F Villa

Fannie Mori

Jacques Montplaisir

Affiliations

Soon will be listed here.

Abstract

Introduction: Narcolepsy patients report lower health-related quality of life (HRQoL) than the general population, as measured by the Short Form-36 Health Survey (SF-36). This analysis evaluated whether changes in SF-36 correlated with physician-rated Clinical Global Impression of Change (CGI-C).

Methods: Data were from 209 of 228 narcolepsy patients participating in an 8-week clinical trial of sodium oxybate. Changes from baseline for SF-36 subscales (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health) and the summary scores were evaluated for correlation with CGI-C overall and by treatment group. Correlations were calculated using the Pearson product-moment correlation coefficient (r).

Results: Correlations described an inverse relationship in scores, but a direct relationship in improvement; lower CGI-C scores (i.e., better) were associated with higher SF-36 subscale scores (i.e., improved HRQoL). Moderate and significant correlations were observed for Vitality (r = -0.464; P < 0.0001) and Role Physical (r = -0.310; P < 0.0001) subscales, but weak correlations were observed with other subscales including summary scores. Correlations were stronger at higher sodium oxybate doses for most SF-36 subscales.

Conclusion: Some aspects of HRQoL, measured by the SF-36, may be associated with narcolepsy. In particular, Vitality (indicative of energy and tiredness) and Role Physical (impact of physical function on daily roles) moderately correlated with overall change in status observed by clinicians. However, lack of strong correlations between SF-36 and CGI-C indicates differences in patient and clinician perspectives of disease, and suggest a need for broader assessment of the impact of narcolepsy and its treatment on patients.

Funding: Jazz Pharmaceuticals.

Citing Articles

Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness.

Weaver T, Mathias S, Crosby R, Bron M, Bujanover S, Menno D J Sleep Res. 2020; 30(3):e13210.

PMID: 33051943 PMC: 8244115. DOI: 10.1111/jsr.13210.

Prevalence of Depression or Depressive Symptoms in Patients with Narcolepsy: a Systematic Review and Meta-Analysis.

Li X, Sanford L, Zong Q, Zhang Y, Tan L, Li T Neuropsychol Rev. 2020; 31(1):89-102.

PMID: 32671534 DOI: 10.1007/s11065-020-09443-7.

References

Jennum P, Knudsen S, Kjellberg J . The economic consequences of narcolepsy. J Clin Sleep Med. 2009; 5(3):240-5. PMC: 2699169. View

. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med. 2005; 6(5):415-21. DOI: 10.1016/j.sleep.2005.03.010. View

David A, Constantino F, Moutinho Dos Santos J, Paiva T . Health-related quality of life in Portuguese patients with narcolepsy. Sleep Med. 2012; 13(3):273-7. DOI: 10.1016/j.sleep.2011.06.021. View

Dodel R, Peter H, Spottke A, Noelker C, Althaus A, Siebert U . Health-related quality of life in patients with narcolepsy. Sleep Med. 2007; 8(7-8):733-41. DOI: 10.1016/j.sleep.2006.10.010. View

Yalcin I, Viktrup L . Comparison of physician and patient assessments of incontinence severity and improvement. Int Urogynecol J Pelvic Floor Dysfunct. 2007; 18(11):1291-5. DOI: 10.1007/s00192-007-0326-8. View

Dodel R, Peter H, Walbert T, Spottke A, Noelker C, Berger K . The socioeconomic impact of narcolepsy. Sleep. 2004; 27(6):1123-8. DOI: 10.1093/sleep/27.6.1123. View

Vignatelli L, DAlessandro R, Mosconi P, Ferini-Strambi L, Guidolin L, De Vincentiis A . Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey. Sleep Med. 2004; 5(5):467-75. DOI: 10.1016/j.sleep.2004.04.003. View

Ervik S, Abdelnoor M, Heier M, Ramberg M, Strand G . Health-related quality of life in narcolepsy. Acta Neurol Scand. 2006; 114(3):198-204. DOI: 10.1111/j.1600-0404.2006.00594.x. View

Daniels E, King M, Smith I, Shneerson J . Health-related quality of life in narcolepsy. J Sleep Res. 2001; 10(1):75-81. DOI: 10.1046/j.1365-2869.2001.00234.x. View

10.

Bogan R, Swick T, Mamelak M, Kovacevic-Ristanovic R, Lai C, Black J . Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial. Neurol Ther. 2016; 5(2):203-213. PMC: 5130920. DOI: 10.1007/s40120-016-0053-5. View

11.

Vignatelli L, Plazzi G, Peschechera F, Delaj L, DAlessandro R . A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Med. 2010; 12(1):19-23. DOI: 10.1016/j.sleep.2010.07.008. View

12.

Tabolli S, Sampogna F, Pagliarello C, Paradisi A, Spagnoli A, Abeni D . Disease severity evaluation among dermatological out-patients: a comparison between the assessments of patients and physicians. J Eur Acad Dermatol Venereol. 2012; 26(2):213-8. DOI: 10.1111/j.1468-3083.2011.04038.x. View

13.

Beusterien K, Rogers A, Walsleben J, Emsellem H, Reblando J, Wang L . Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 1999; 22(6):757-65. DOI: 10.1093/sleep/22.6.757. View

14.

Droogleever Fortuyn H, Fronczek R, Smitshoek M, Overeem S, Lappenschaar M, Kalkman J . Severe fatigue in narcolepsy with cataplexy. J Sleep Res. 2011; 21(2):163-9. DOI: 10.1111/j.1365-2869.2011.00943.x. View

15.

. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2007; 1(4):391-7. View

16.

Black J, Reaven N, Funk S, McGaughey K, Ohayon M, Guilleminault C . The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings. Sleep Med. 2014; 15(5):522-9. DOI: 10.1016/j.sleep.2014.02.001. View

17.

Campbell A, Signal T, OKeeffe K, Bakker J . Narcolepsy in New Zealand: pathway to diagnosis and effect on quality of life. N Z Med J. 2011; 124(1336):51-61. View

18.

Bogan R, Roth T, Schwartz J, Miloslavsky M . Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med. 2015; 11(4):427-32. PMC: 4365456. DOI: 10.5664/jcsm.4598. View

19.

Ozaki A, Inoue Y, Nakajima T, Hayashida K, Honda M, Komada Y . Health-related quality of life among drug-naïve patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Med. 2008; 4(6):572-8. PMC: 2603535. View

20.

Flores N, Villa K, Black J, Chervin R, Witt E . The Humanistic and Economic Burden of Narcolepsy. J Clin Sleep Med. 2015; 12(3):401-7. PMC: 4773621. DOI: 10.5664/jcsm.5594. View